Picture of Zhaoke Ophthalmology logo

6622 — Zhaoke Ophthalmology News Story

0.000.00%
hk flag iconLast trade - 00:00
HealthcareSpeculativeSmall CapSucker Stock

Brief: Zhaoke Ophthalmology Says Phase III Trial Of Cyclosporine A Ophthalmic Gel Met Primary Endpoint

Aug 17 (Reuters) - Zhaoke Ophthalmology Ltd  6622.HK :
    * PHASE III CLINICAL TRIAL OF CYCLOSPORINE A OPHTHALMIC GEL
FOR
TREATMENT OF DRY EYE DISEASE MET ITS PRIMARY ENDPOINT
    * CONTINUES TO TARGET SUBMISSION OF A NDA TO NMPA BY END OF
2021


Further company coverage:  6622.HK 

 (Reuters.Briefs@thomsonreuters.com)

Recent news on Zhaoke Ophthalmology

See all news